Skip to main content
. 2017 Sep 23;8(49):86488–86502. doi: 10.18632/oncotarget.21212

Figure 4. Effect of PSC-derived Galectin-1 on in vivo orthotopic xenograft establishment and growth.

Figure 4

(A) PANC-1 mixed with PSCs were implanted orthotopically into the pancreas of nude mice (n = 5). The mice were sacrificed and the xenografts were removed on day 30 after cell implantation. The red star represent cases with liver metastasis. (B) H&E staining of samples of orthotopic xenografts in the pancreas of nude mice. (C) Proliferating capability of the orthotopic xenograft was evaluated using the EdU incorporation assay, and the number of EdU positive cells per micro field is shown in (F). Tumor volume (D) and weight (E) is expressed as the mean ± SE. *p < 0.05, **p < 0.01, #p > 0.05 vs. wt-Galectin-1 PSCs.